Clinical Trial

To Investigate REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice

Study acronym: LYCHEE
Recruiting
View on ClinicalTrials.gov →
Summary
This is a multi-centre prospective non-interventional trial to assess the pattern of use of REKOVELLE® in Women Undergoing In Vitro Fertilisation (IVF) or Intracytoplasmic Sperm Injection (ICSI) Procedures in Routine Clinical Practice. There will be approximately 2500 patients initiated with REKOVELLE® treatment and enrolled in 30-50 sites in China. The total duration of the study will be approximately 35 months.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-17; most recent amendment 2026-01-16.
Status change: Not Yet Recruiting → Recruiting 2025-08-15
Trial Details
NCT Number NCT07029451
Lead Sponsor Ferring Pharmaceuticals
Conditions Infertility
Enrollment 2,500 participants
Start Date 2025-08-05
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-20